{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:20:42Z","timestamp":1786242042278,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023673","name":"Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2601"],"award-info":[{"award-number":["IMSIU-DDRSP2601"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jmgm.2026.109310","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:24:13Z","timestamp":1769901853000},"page":"109310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent"],"prefix":"10.1016","volume":"144","author":[{"given":"Nemat","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Alaseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arockia","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glowi","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3190-0151","authenticated-orcid":false,"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jmgm.2026.109310_bib1","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1039\/C8QO00706C","volume":"5","author":"Joshi","year":"2018","journal-title":"Org. Chem. Front."},{"issue":"3","key":"10.1016\/j.jmgm.2026.109310_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.jmgm.2026.109310_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.jmgm.2026.109310_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.pharep.2017.02.013","article-title":"Partial protection by 18\u03b2 Glycrrhetinic acid against Cisplatin induced oxidative intestinal damage in wistar rats: possible role of NFkB and caspases","volume":"69","author":"Rashid","year":"2017","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.jmgm.2026.109310_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1871520615666150819121106","article-title":"Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review","volume":"16","author":"Kaur","year":"2016","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.jmgm.2026.109310_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1389450117666151209123402","article-title":"A perspective on monoamine oxidase enzyme as drug target: challenges and opportunities","volume":"18","author":"Kumar","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.jmgm.2026.109310_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a molecular target in cancer","volume":"108","author":"Brand","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"42","key":"10.1016\/j.jmgm.2026.109310_bib8","first-page":"4729","article-title":"Promising targets in anti-cancer drug development: recent updates","volume":"24","author":"Kumar","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.jmgm.2026.109310_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","article-title":"EGF receptor","volume":"31","author":"Wells","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"7","key":"10.1016\/j.jmgm.2026.109310_bib10","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1039\/D4MD00237G","volume":"15","author":"Kumar","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"8","key":"10.1016\/j.jmgm.2026.109310_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1039\/D0MD00146E","article-title":"Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition","volume":"11","author":"Kalra","year":"2020","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.jmgm.2026.109310_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbcan.2006.06.001","article-title":"The complexity of targeting EGFR signalling in cancer: from expression to turnover","volume":"1766","author":"Sebastian","year":"2006","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.jmgm.2026.109310_bib13","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2165\/00003495-200767140-00006","article-title":"EGFR, HER2 and VEGF pathways: validated targets for cancer treatment","volume":"67","author":"Press","year":"2007","journal-title":"Drugs"},{"issue":"S4","key":"10.1016\/j.jmgm.2026.109310_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","article-title":"Why the epidermal growth factor receptor? The rationale for cancer therapy","volume":"7","author":"Baselga","year":"2002","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.jmgm.2026.109310_bib15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non\u2013small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jmgm.2026.109310_bib16","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non\u2013small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jmgm.2026.109310_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jsps.2020.03.002","article-title":"Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK\/NF-\u03baB signaling pathways","volume":"28","author":"AlAsmari","year":"2020","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"10.1016\/j.jmgm.2026.109310_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtho.2018.01.009","article-title":"EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib","volume":"13","author":"Kobayashi","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.jmgm.2026.109310_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/adt.2022.120","article-title":"Design, synthesis, molecular docking, and biological evaluation of isatin-based fused heterocycles as epidermal growth factor receptor inhibitors","volume":"21","author":"Kumar","year":"2023","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.jmgm.2026.109310_bib20","series-title":"Drug Repurposing","author":"Poduri","year":"2023"},{"key":"10.1016\/j.jmgm.2026.109310_bib21","series-title":"Drug Repurposing","first-page":"221","article-title":"11 Drug repurposing of drugs from natural and marine origins","author":"Roy","year":"2023"},{"key":"10.1016\/j.jmgm.2026.109310_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"16","key":"10.1016\/j.jmgm.2026.109310_bib23","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"6","key":"10.1016\/j.jmgm.2026.109310_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70023","article-title":"Design and development of novel hybrids based on pyrrolo [2, 1\u2010f][1, 2, 4] triazine and 1\u2010(Methylpiperidin\u20104\u2010yl) aniline\u2013based analogs: exploring the utility as anticancer agents via MERTK inhibition","volume":"104","author":"Sathe","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.jmgm.2026.109310_bib25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jmgm.2026.109310_bib26","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"issue":"4","key":"10.1016\/j.jmgm.2026.109310_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/qsar.200730051","article-title":"Benchmarking the reliability of QikProp. Correlation between experimental and predicted values","volume":"27","author":"Ioakimidis","year":"2008","journal-title":"QSAR Comb. Sci."},{"key":"10.1016\/j.jmgm.2026.109310_bib28","series-title":"Qikprop, Version 3.5 (NY)","author":"Schr\u00f6dinger","year":"2012"},{"key":"10.1016\/j.jmgm.2026.109310_bib29","unstructured":"Release, S., 1: Desmond Molecular Dynamics System, Version 3.7. DE Shaw Research, New York, NY, Maestro-Desmond Interoperability Tools, version, 2014. 3."},{"key":"10.1016\/j.jmgm.2026.109310_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-2074-7_26","article-title":"General Cytotoxicity Assessment by Means of the MTT Assay","volume":"1250","author":"Tolosa","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"31","key":"10.1016\/j.jmgm.2026.109310_bib31","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17243","article-title":"Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmgm.2026.109310_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116976","article-title":"Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6, 7, 8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors","volume":"72","author":"Dwivedi","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jmgm.2026.109310_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133592","article-title":"Design, synthesis and evaluation of 4-phenyl-1, 2, 3-triazole substituted pyrimidine derivatives as antiproliferative and tubulin polymerization inhibitors","volume":"1267","author":"Dwivedi","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jmgm.2026.109310_bib34","series-title":"In Xpharm: the Comprehensive Pharmacology Reference","author":"Scholar","year":"2007"},{"issue":"6","key":"10.1016\/j.jmgm.2026.109310_bib35","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/jm00300a026","article-title":"Irreversible enzyme inhibitors. CLXXIII. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4, 6-diamino-1, 2-dihydro-2, 2-dimethyl-s-triazine","volume":"13","author":"Baker","year":"1970","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jmgm.2026.109310_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/metabo13020151","article-title":"Cycloguanil and analogues potently target DHFR in cancer cells to elicit anti-cancer activity","volume":"13","author":"Brown","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jmgm.2026.109310_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3389\/fphar.2018.00899","article-title":"Inhibition of chloride intracellular channel 1 (CLIC1) as biguanide class-effect to impair human glioblastoma stem cell viability","volume":"9","author":"Barbieri","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326326000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326326000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:54:24Z","timestamp":1774011264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326326000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S1093326326000367"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2026.109310","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2026.109310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109310"}}